Endocrine disruptors and prostate cancer risk.
There is increasing evidence both from epidemiology studies and animal models that specific endocrine-disrupting compounds may influence the development or progression of prostate cancer. In large part, these effects appear to be linked to interference with estrogen signaling, either through interacting with ERs or by influencing steroid metabolism and altering estrogen levels within the body. In humans, epidemiologic evidence links specific pesticides, PCBs and inorganic arsenic exposures to elevated prostate cancer risk. Studies in animal models also show augmentation of prostate carcinogenesis with several other environmental estrogenic compounds including cadmium, UV filters and BPA. Importantly, there appears to be heightened sensitivity of the prostate to these endocrine disruptors during the critical developmental windows including in utero and neonatal time points as well as during puberty. Thus infants and children may be considered a highly susceptible population for ED exposures and increased risk of prostate cancers with aging.
Prins
Gail S
GS
Department of Urology, University of Illinois at Chicago, Chicago, Illinois 60612, USA. gprins@uic.edu
D000383:Agriculture; D000726:Androgen Antagonists / Q000633:toxicity; D052244:Endocrine Disruptors / Q000506:poisoning / Q000633:toxicity*; D004781:Environmental Exposure / Q000009:adverse effects; D006801:Humans; D008297:Male; D010575:Pesticides / Q000506:poisoning; D011471:Prostatic Neoplasms / Q000139:chemically induced*; D012307:Risk Factors
D000726:Androgen Antagonists; D052244:Endocrine Disruptors; D010575:Pesticides